Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ginning at 8 P.M. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4106309.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals and expected timing of clinical studies, including the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the timing and design of Phase 3 clinical development for Amigal, the Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the effect of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... STATION, Texas , July 28, 2014   The ... a 177-key, 4-star boutique hotel in the heart of The Atlas ... Photo - http://photos.prnewswire.com/prnh/20140725/130455 Photo ... within ATLAS , The Atlas ... rooms and suites, a sleek restaurant and bar, a wellness spa, ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
(Date:7/25/2014)... Livermore, California (PRWEB) July 25, 2014 ... been named to Thomson Reuters list of " The ... Pitz are part of the 3,000 researchers who were ... years to recognize those who published the highest-impact work ... numerous research papers on combustion modeling . , ...
Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will Webcast ... 2008 on Tuesday, October 21, 2008 at 5:00 p.m. ... Executive,Officer, will lead the call. On the same date ... of 2008., The call will be Webcast live ...
... Data Demonstrates 30% Reduction in Composite Events When Using Routine ... FFR Guidance in ... VOLC ) today announced the launch of the PrimeWire(TM) Pressure,Guidewire, ... s5 and,s5i imaging consoles in the U.S. The PrimeWire is ...
... Colo., Oct. 15 Bolder BioTechnology, Inc.,announced today ... Phase II Continuing,Renewal Small Business Innovation Research (SBIR) ... the National,Institute of Neurological Disorders and Stroke (NINDS) ... the entire grant award is contingent,upon the achievement ...
Cached Biology Technology:Amylin Pharmaceuticals to Webcast Third Quarter Results 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... Amundsen became the first man to reach the South ... later, an international team of scientists led by Joe ... that air pollution from industrial activities arrived long before. ... widely spaced locations around the Antarctic continent, including the ... precise reconstruction to date of lead pollution over the ...
(Date:7/27/2014)... fungi can evade treatment by acquiring mutations in the ... mutations were once thought to be the only way ... has shown that microorganisms can use a temporary silencing ... gain the benefits of drug resistance without the commitment. ... fungus called Mucor circinelloides, it is likely to be ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... lipid synthesis in the liver, UC Irvine endocrinologists have revealed ... With this finding, Dr. Ellis Levin and colleagues believe ... appear in the May 21 issue of the journal ... field for 50 years has been that only receptors located ...
... health, development, and academic success of children, schools should ... have opportunities to engage in at least 60 minutes ... a new report from the Institute of Medicine. ... children meet this evidence-based guideline for promoting better health ...
... (May 23, 2013) A new report from the ... pupils engage in at least 60 minutes of vigorous or ... than half of American youth meet current evidence-based guidelines of ... activity daily, according to the report, which was released today. ...
Cached Biology News:UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
... PGE1-d4 contains 4 deuterium atoms at ... It is intended for use as an ... by GC- or LC-mass spectrometry. PGE1 is ... (DGLA), but it is virtually undetectable in ...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: